Skip to content

Effect of change in pancreas and liver fat content upon beta cell function and hepatic insulin action during weight loss in type 2 diabetes

Effect of change in pancreas and liver fat content upon beta cell function and hepatic insulin action during weight loss in type 2 diabetes: a non-randomised interventional treatment trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN57022672
Enrollment
22
Registered
2010-04-23
Start date
2009-10-01
Completion date
Unknown
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Diabetes Research Network, Primary Care Research Network for England

Interventions

The study involves an 8-week period of very low calorie diet (800 cal per day) using liquid based-formula diet (Optifast®) to induce weight loss. In addition to the three sachets of Optifast® per day,

Sponsors

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: For type 2 diabetes volunteers: 1. Duration of diabetes up to 2 years 2. Aged between 25 - 65 years, either sex 3. Body mass index (BMI) of 30 - 40 kg/m^2 with stable body weight for preceeding 3 months 4. HbA1c between 6.2 and 9.0% 5. On treatment with diet alone or diet plus metformin For healthy controls: 1. Normal glucose tolerance plasma fasting triglyceride less than 1.8 mmol/l 2. No family history of type 2 diabetes 3. Matching BMI and age

Exclusion criteria

Exclusion criteria: 1. Kidney dysfunction (serum creatinine greater than 150 micromol/l) 2. Liver dysfunction (serum alanine aminotransferase [ALT] greater than 2.5 upper limit normal) 3. Contraindications to magnetic resonance imaging (MRI) (metal implants and claustrophobia) 4. Consumption of greater than 14 units of alcohol per week 5. Treatment with sulphonylureas, thiazolidinediones, steroids or beta-blockers

Design outcomes

Primary

MeasureTime frame
1. Liver fat content 2. Pancreatic fat content 3. Hepatic insulin sensitivity 4. Glucose-induced insulin secretion Each of the above is measured at baseline, week 1, week 4 and week 8.

Secondary

MeasureTime frame
Glucose control

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026